

Sodium Channels

Flecainide

Open Na⁺ channel blocker that inhibits fast Na⁺ current in cardiac muscle in a use- and concentration-dependent manner.^{1,2}

Product No: 10-2992 **10 mg** **50 mg**

A-803467

Potent, selective inhibitor of the TTX-resistant voltage-gated sodium channel Nav1.8. IC₅₀s for rat and human Nav1.8 are 140 nM and 8.0 nM respectively.^{3,4}

Product No: 10-1066 **10 mg** **50 mg**

Veratridine

Steroidal alkaloid. Voltage-gated Na⁺ channel activator. Cell permeable.⁵

Product No: 10-1017 **10 mg** **50 mg**

Ambroxol

Sodium channel blocker that inhibits TTX-r channels (Nav1.8) with higher potency than TTX-s channels (30 μM vs 100 μM). Also inhibited inactivated channels 5.5x more potently than resting channels.⁶

Product No: 10-2296 **50 mg** **250 mg**

Ranolazine

Selective blocker of the late sodium channel current.⁷ Blocks Nav1.4, 1.5, 1.7 and 1.8 (IC₅₀'s = 2.4⁸, 6.2⁸, 1.7⁸(10.3)⁹, 21.5 μM⁹ respectively).

Product No: 10-3701 **10 mg** **50 mg**

Lorcainide HCl

Blocks sodium channels in a voltage- and frequency-dependent manner.¹⁰

Product No: 10-1157 **5 mg** **25 mg**

AA43279

Selective Nav1.1 activator.¹¹

Product No: 10-3503 **5 mg** **25 mg**

ICA-121431

Selective Nav1.1/1.3 inhibitor.¹²

Product No: 10-4085 **5 mg** **25 mg**

PF-05089771

Selective state-dependent Nav1.7 inhibitor.¹³

Product No: 10-3990 **5 mg** **25 mg**

Riluzole


Blocker of the persistent sodium current (I_{NaP}). It can also block potassium and calcium currents as well as react with GABA_A and glycine receptors.¹⁴

Product No: 10-2815 **20 mg** **100 mg**


Rufinamide

Clinically useful anticonvulsant medication whose mechanism of action is believed to be inhibition of Nav1.1 and Nav1.6 activation.¹⁵

Product No: 10-4275 **10 mg** **50 mg**



AA43279



PF-05089771

REFERENCES

1. Rouet and Ducouret (1994) J.Cardiovasc. Pharmacol. **24** 177
2. Singh *et al.* (1984) Ann. NY Acad. Sci. **432** 210
3. Jarvis, *et al.* (2007) PNAS **104** 8520
4. McGaraughty, *et al.* (2008) J.Pharmacol.Exp.Ther. **324** 1204
5. Catteral *et al.* (2005) Pharmacol.Rev. **57** 397
6. Gaida *et al.* (2005) Neuropharmacology **49** 1220
7. Belardinelli *et al.* (2006) Heart **92** iv6
8. Wang *et al.* (2008) Mol.Pharmacol. **73** 940
9. Rajamani *et al.* (2008) Channels **2** 449
10. Sheldon *et al.* (1989) Clin. Chem. **35** 748
11. Fredericksen *et al.* (2017) Eur. J. Neuroscience **46** 1887
12. McCormack *et al.* (2013) PNAS **110** E2724
13. Swain *et al.* (2017) J. Med. Chem. **60** 7029
14. Lamanuskas and Nistri (2008) Eur. J. Neurosci. **27** 2501
15. Gilchrist *et al.* (2014) ACS Chem. Biol. **9** 1204